Technical Analysis for MDNA - Medicenna Therapeutics Corp.

Grade Last Price % Change Price Change
B 1.640 -1.80% -0.030
MDNA closed down 1.8 percent on Friday, April 19, 2024, on 47 percent of normal volume.
1 Watcher
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Down

Date Alert Name Type % Chg
Wide Bands Range Expansion 0.00%
Down 3 Days in a Row Weakness 0.00%
Down 4 Days in a Row Weakness 0.00%
Down 5 Days in a Row Weakness 0.00%
20 DMA Resistance Bearish -1.80%
Calm After Storm Range Contraction -1.80%
NR7 Range Contraction -1.80%
Wide Bands Range Expansion -1.80%
Down 3 Days in a Row Weakness -1.80%
Down 4 Days in a Row Weakness -1.80%

   Recent Intraday Alerts

Alert Time
Down 5% 1 day ago
Down 3% 1 day ago
Down 2% 1 day ago
Possible NR7 2 days ago
Fell Below Previous Day's Low 2 days ago

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Medicenna Therapeutics Corp. Description

Medicenna Therapeutics Corp, formerly A2 Acquisition Corp, is a Canada-based clinical stage immuno-oncology company. The Company is engaged in developing engineered versions of Interleukin (IL)-2, IL4 and IL13 cytokines called Superkines and Empowered Cytokines (ECs). The Company focuses on commercialization EC and Superkines for the treatment of cancer. The Company's IL4 EC is a drug that targets the Bulk Tumor, Cancer Stem Cells and Immunosuppressive Cells of the Tumor Micro-environment. MDNA55 is the Company's lead product. MDNA55 is being studied in clinical trials for treatment of CNS cancers. The Company's MDNA56 and MDNA57 are its IL-4 carrying a human cell killing payload. MDNA56 is being developed for the treatment of hematopoietic cancers expressing the Type 1 IL-4R, whereas MDNA57 is intended to selectively target solid tumors and non-malignant cells of the tumor micro-environment expressing the Type 2 IL-4R.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Clinic Drug Cancer Medical Specialties Clinical Trial Oncology Clinical Medicine Cancers Tumor Immunotherapy Stem Cells Treatment Of Cancer Cancer Immunotherapy Tumors

Is MDNA a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 2.1
52 Week Low 0.215
Average Volume 173,945
200-Day Moving Average 0.696
50-Day Moving Average 1.396
20-Day Moving Average 1.751
10-Day Moving Average 1.781
Average True Range 0.187
RSI (14) 50.25
ADX 29.97
+DI 23.354
-DI 23.304
Chandelier Exit (Long, 3 ATRs) 1.538
Chandelier Exit (Short, 3 ATRs) 1.942
Upper Bollinger Bands 2.048
Lower Bollinger Band 1.454
Percent B (%b) 0.31
BandWidth 33.916
MACD Line 0.103
MACD Signal Line 0.145
MACD Histogram -0.0428
Fundamentals Value
Market Cap 80.36 Million
Num Shares 49 Million
EPS -0.19
Price-to-Earnings (P/E) Ratio -8.82
Price-to-Sales 0.00
Price-to-Book 7.03
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.850
Resistance 3 (R3) 1.853 1.787 1.815
Resistance 2 (R2) 1.787 1.733 1.785 1.803
Resistance 1 (R1) 1.713 1.700 1.680 1.710 1.792
Pivot Point 1.647 1.647 1.630 1.645 1.647
Support 1 (S1) 1.573 1.593 1.540 1.570 1.488
Support 2 (S2) 1.507 1.560 1.505 1.477
Support 3 (S3) 1.433 1.507 1.465
Support 4 (S4) 1.430